Background
==========

Nosocomial infections are frequent complications of hospitalization and also an important public health problem in developing countries, as well as in developed ones. The socioeconomic impact, ie, prolongation of hospitalization, mortality, and cost of these infections adversely effects patients and nations\' economic well-being \[[@B1]\]. The cost of nosocomial infections includes increased length of hospital stay, staff time, laboratory cultures of pathogens and antimicrobial treatment \[[@B2]-[@B4]\]. Although, cost of antimicrobial treatment is an important part of health expenditure, data on this subject are extremely limited in Turkey.

The aim of our study was to determine daily antibiotic cost of nosocomial infection per infected patient in a university hospital.

Methods
=======

The hospital setting
--------------------

Akdeniz University Hospital is a 600-bed tertiary referral centre in Antalya, Turkey, treating 27 000 patients per year. The study was conducted in six adult medical and surgical intensive care units (ICUs) with a total of 51 ICU beds. Neonatal ICU was not included in the study. Since 1993, the institutional policies of hospital infection control have been implemented by infection control team.

Definitions and study population
--------------------------------

In our hospital, routine prospective, active surveillance of nosocomial infections in all ICUs is performed by one infection control nurse, supervised by an infection control physician. Nosocomial infections are defined using the Centers for Disease Control and Prevention criteria \[[@B5],[@B6]\]. We do not follow patients for signs of infection after discharge unless they are readmitted to the hospital.

Between January 1, 2000 and June 30, 2003, all inpatients hospitalized in one of the adult ICUs were included in this study. Data on antimicrobial treatment were recorded for patients aged 15 or above presenting with only one nosocomial infection. For all patients included in the study, the following were recorded: age, sex, infection site, microbiologic data, antimicrobial therapy and antibiotic cost.

Measurement of costs
--------------------

In our ICUs, all antimicrobial prescriptions are recommended by an infectious disease consultant. Antimicrobial agents prescribed only for therapeutic indications were recorded. The daily antibiotic cost was calculated in US dollars based on June 2003 prices of antimicrobial agents provided by the hospital pharmacy. The daily antibiotic cost per infected patient was calculated by the multiplication of box price and number of daily doses that was used for that infection. Two costs were calculated for each antimicrobial; the minimal cost (min) was based on the lowest recommended parenteral daily dose and the maximal cost (max) was based on the highest recommended parenteral daily dose.

Results
=======

Between January 1, 2000, and June 30, 2003, a total of 8460 patients were admitted to the adult ICUs. Overall, 817 patients developed 1407 episodes of nosocomial infections, accounting for an infection rate of 16,6%. Among them, 233 patients (mean age:50,1; sex ratio female:male 0,49) had only one nosocomial infection. Mean daily antibiotic cost was found \$89,64 per infected patient (\$8,56 to \$359,28).

Among the sites of nosocomial infections, urinary tract infections had the lowest daily antibiotic cost per infected patient (Table [1](#T1){ref-type="table"}). The mean daily antibiotic cost for pneumonia was the highest of all sites, but patients with bloodstream infection reached the highest range of daily cost (\$31,31 to \$359,28). In addition, mean daily antibiotic cost was found \$162,35 for seventeen other infections including postoperative meningitis, mediastinitis, and empyema.

###### 

Daily antibiotic costs according to the sites of nosocomial infections.

  Site of nosocomial infections   Number of patients   Range of daily cost per infected (US\$)   Mean (US\$)
  ------------------------------- -------------------- ----------------------------------------- -------------
  Pneumonia                       111                  10,02--250,74                             99,02
  Bloodstream infections          28                   31,31--359,28                             94,32
  Surgical site infections        11                   17,12--204,74                             94,31
  Urinary tract infections        66                   8,56--228,68                              52,37

Out of 233 patients, 206 patients had microbiologically documented infections, 177 patients were infected by a single pathogen while 29 patients were diagnosed as having polymicrobial infections (Table [2](#T2){ref-type="table"}). *Pseudomonas aeruginosa*was the most prevalent bacteria followed by *Klebsiella*spp. and *Acinetobacter*spp.. *P. aeruginosa*infections had the highest overall daily antibiotic cost per infected patient than other pathogens. Among 21 *Staphylococcus aureus*strains 15 (72%) were resistant to methicillin. The overall daily antibiotic cost of methicillin resistant *S. aureus*(MRSA) infections was two to three times higher than infections with susceptible strains. However, median daily cost per infected patient for MRSA infections were lower than susceptible strain infections.

###### 

Daily antibiotic cost according to the pathogens.

  Pathogens                        No.   Overall daily cost (US\$)   Range of daily cost per pathogen (US\$)   Median (US\$)
  -------------------------------- ----- --------------------------- ----------------------------------------- ---------------
  *Pseudomonas aeruginosa*         60    5567,06                     17,98--204,74                             100,04
  *Acinetobacter*spp               36    4951,06                     17,98--359,28                             92,47
  *Stenotrophomonas maltophilia*   4     310,99                      31,31--100,04                             89,82
  *Klebsiella*spp                  37    3104,22                     10,02--179,64                             79,6
  *Enterobacter*spp                10    961,79                      60,42--139,08                             77,28
  *Escherichia coli*               23    1652,57                     10,02--179,64                             60,41
  *Proteus*spp                     3     49,04                       13,24--49,04                              49,04
                                                                                                               
  *Staphylococcus aureus*                                                                                      
                                                                                                               
  Methicillin-susceptible (MS)     6     476,22                      10,02--142,2                              74,52
  Methicillin-resistance (MR)      15    1188,1                      35,88--142,2                              71,1
                                                                                                               
  CoNS\*                                                                                                       
                                                                                                               
  MS-CoNS                          1     49,64                       16,34--49,64                              49,64
  MR-CoNS                          3     148,92                      17,52--49,64                              49,64
  *Enterococcus*spp                16    1141,25                     32,29--142,2                              49,64
  *Candida*spp                     21    235,52                      8,56--38,64                               8,56
  No pathogen identified           27    3166,75                     10,02--359,28                             114,6

\* Coagulase negative *Staphylococcus*

Among the 350 antibiotic prescriptions for nosocomial infections, piperacillin-tazobactam and amikacin were the most prescribed antibiotics (Table [3](#T3){ref-type="table"}). Carbapenems especially meropenem were the most expensive drugs.

###### 

Daily cost of antimicrobial agents for nosocomial infections.

  Antimicrobial agents              Number of prescriptions   Daily cost per infected (US\$)   
  --------------------------------- ------------------------- -------------------------------- --------
  Betalactams                                                                                  
                                                                                               
  Ampicillin-sulbactam              20                        23,92                            71,76
  Piperacillin-tazobactam           48                        85,95                            114,6
  Ticarcillin-clavulanate           4                         14,9                             22,35
                                                                                               
  Carbapenems                                                                                  
                                                                                               
   Imipenem                         31                        100,04                           150,06
   Meropenem                        23                        179,64                           359,28
                                                                                               
  Cephalosporins                                                                               
                                                                                               
   Cefepime                         26                        38,64                            77,28
   Ceftazidime                      18                        35,82                            71,64
   Cefoperazone-sulbactam           16                        40,28                            80,56
   Cefazoline                       10                        10,02                            20,04
   Ceftriaxone                      3                         19,7                             39,4
                                                                                               
  Aminoglycosides\*                                                                            
                                                                                               
   Amikacin                         52                        \-                               7,96
   Netilmicin                       21                        \-                               24,48
   Tobramycin                       3                         \-                               18,56
                                                                                               
  Fluoroquinolones                                                                             
                                                                                               
   Ciprofloxacin                    18                        49,04                            98,08
   Ofloxacin                        2                         25,74                            51,48
   Levofloxacin                     1                         41,07                            82,14
                                                                                               
  Glycopeptides                                                                                
                                                                                               
   Vancomycin                       13                        49,64                            87,27
   Teicoplanin                      12                        71,1                             142,2
                                                                                               
  Other antibiotics                                                                            
                                                                                               
   Clarithromycin                   4                         11,57                            23,14
   Trimethoprim-sulphamethoxazole   2                         4,48                             8,96
   Metronidazole                    2                         5,51                             10,04
                                                                                               
  Antifungal agents                                                                            
                                                                                               
   Fluconazole                      21                        8,56                             34,24
  Total                             350                       8,56                             359,28

\* dosage given as once-daily.

Disscussion
===========

Cost is an important factor which determines the physician\'s choice of medication to treat patients in spesific stiuations. In this study, we tried to demonstrate the daily cost of antimicrobial treatment of nosocomial infections according to site of infection, pathogen and antimicrobial agent.

In different studies, economical analysis regarding costs attributable to nosocomial infections has been evaluated and reported between \$1018 to 2280 per infected patient \[[@B7]-[@B9]\]. Jarvis et al reported that the estimated average costs of nosocomial infections were \$558 to 593 for each urinary tract infection, \$2734 for each surgical site infection, \$3061 to 40000 for each bloodstream infection, and \$4947 for each pneumonia \[[@B1]\].

Daily cost of antimicrobial treatment has been reported to be a significant extra cost attributable to nosocomial infections. In this study, we found an average daily antibiotic cost of \$89,64 per nosocomial infection. It is clear that cost of overall antibiotic treatment for a period of approximately 10--15 days is \$900 to \$1350. Prolongation of hospital stay has been the major extra cost attributable to nosocomial infections in many reports \[[@B2]-[@B4]\], but in comparative case-control study from our country, Yalcin et al. \[[@B8]\] found that cost of antibiotic therapy of \$1190 per infected patient, accounted for about 75% of the total extra cost. This finding may be due to the high prices of antibiotics in Turkey. To calculate the true costs of antibiotic therapy, hidden costs arising from intravenous administration, labor, serum antibiotic assay, monitoring hematological and biochemical indices and adverse effects of antibiotics must be considered \[[@B10]\]. The present study does not include these relevant \"hidden costs\" that could substantially modify the total cost of an antibiotic treatment. Although, hidden costs were not calculated, an average daily antibiotic cost of a single nosocomial infection is found to be markedly high in our hospital.

This result is within the limits reported by other large economic studies, suggesting that our data is comparable to those found in other countries and with other assessment methods. In a French prevalence survey, Astagneau et al.\[[@B11]\] reported an average daily antibiotic cost between FF 520 to 1085 (about \$86 to \$160) per nosocomial infection. French et al.\[[@B12]\] and Haley et al.\[[@B13]\] reported an average cost of antibiotic treatment of \$190 and between \$72 to \$128 per nosocomial infection, respectively. In Turkey, Yalcin et al.\[[@B14]\] found that daily antibiotic cost of nosocomial infections was \$70 per patient.

The daily antibiotic cost varies markedly according to site of infection. Our study has demonstrated that pneumonia and bloodstream infections were associated with the highest daily antibiotic costs as reported in other studies \[[@B11],[@B13],[@B14]\]. Surgical site infections had also high daily antibiotic cost in our study. In their case-control study, Coello et al. reported that antibiotic therapy for surgical patients was the second most significant contributor to cost \[[@B15]\]. In the present study, nosocomially infected patients that had only one nosocomial infection were considered for analysis. Clearly, antimicrobial treatment of patients with multiple nosocomial infections might be much more expensive.

*P. aeruginosa*infections had the highest daily antibiotic cost followed by other non-fermentative bacilli. Infections caused by *P. aeruginosa*are difficult to treat because of its virulence and relatively limited choice of effective antimicrobial agents, so, these infections often require combination therapy. Emergence of resistance in *P. aeruginosa*has been associated with increased morbidity, mortality, and costs \[[@B16]\]. On the other hand, although the overall antibiotic cost of MRSA infections was higher than infections with susceptible strains, the daily antibiotic cost per infected patient with MRSA was lower with susceptible strain infections. MRSA infections are treated by glycopeptides which cost less than beta-lactams in our country. Astagneau et al reported that the daily antibiotic cost of multi-resistant bacterial infections such as multi-resistant *P. aeruginosa*infections, was 20% higher than susceptible infections, but the daily antibiotic cost per infected patient for MRSA infections was not higher than for susceptible strain infections \[[@B11]\].

Expensive antibiotics, such as piperacillin-tazobactam, carbapenems, cefepime, ciprofloxacin, teicoplanin were prescribed more commonly than the cheaper agents such as ampicillin-sulbactam, ceftriaxone or ofloxacin in our ICUs. These expensive antibiotics were mainly prescribed for resistant and severe gram-negative nosocomial infections, such as ventilator-associated pneumonia and postneurosurgical meningitis in ICU. Physicians may be forced to choose empirical antibiotic therapy with broad spectrum antimicrobials by increasing bacterial multi-resistance.

In conclusion, mean daily antibiotic cost was found \$89,64 per nosocomial infection in our ICUs and nosocomial pneumonia had the highest daily antibiotic cost per infected patient. It is clear that cost of antibiotic therapy of nosocomial infections is an important part of extra cost attributable to nosocomial infection. Approximately one third of nosocomial infections are preventable by full implementation of the current infection control guideline recommendations \[[@B17]\]. Each institution should develope empirical antibiotic guidelines according to its own local nosocomial infections data. Infection control measures, such as education of health care workers regarding antimicrobial agents and resistance; isolation of patients infected with multi-resistant organisms, should be implemented to reduce infections and expensive antibiotic prescriptions.
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